Johnson & Johnson Acquires RIPTAC Pioneer Halda Therapeutics for $3.05B; BeiGene’s HER2 Bispecific Antibody Plus PD-1 Inhibitor Succeeds in Phase III Trial
Johnson & Johnson
Medical Device R&D and Manufacturer
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
WestGene
mRNA Drug R&D and Manufacturing Company
Biokin
Pharmaceutical R&D Developer
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
New Moves in Major Mergers and Acquisitions.
On November 17, Johnson & Johnson announced a full-cash acquisition of Halda Therapeutics, a pioneer in RIPTAC technology, for $3.05 billion. The latter's lead pipeline, HH-0915, used for treating prostate cancer, demonstrated excellent efficacy potential in preliminary clinical trials.
HER2 Bispecific Antibody + PD-1 Presents New Possibilities.
On November 17, BeOne Medicines announced positive results from the Phase III HERIZON-GEA-01 study. The study aimed to evaluate the efficacy and safety of the HER2-targeted bispecific antibody zenidatamab alone or in combination with the PD-1 inhibitor tislelizumab, in addition to combined chemotherapy, as a first-line treatment for HER2-positive locally advanced or metastatic gastric or gastroesophageal adenocarcinoma (GEA, including gastric cancer, gastroesophageal junction adenocarcinoma, and esophageal cancer).
In the past day, what hotspots in the pharmaceutical market at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Pharmaceutical News
1) Junda Jiuzhou GA001 Injection Receives Clinical Approval
On November 18, according to the CDE official website, Junda Jiuzhou's GA001 Injection received clinical approval and is proposed to conduct research for the treatment of retinitis pigmentosa.
2) LBM801 from Bosenmei Biotechnology Receives Clinical Approval
On November 18, according to the CDE official website, BoSaiMei Biologics' LBM801 obtained clinical approval and is proposed for research in osteoarthritis.
3) Wisgen Bio WGc-0201 Injection Receives Clinical Approval
On November 18, according to the CDE official website, Wisgen Biotechnology's WGc-0201 injection has been granted clinical approval for the proposed study to treat HBV-positive hepatocellular carcinoma.
4) Biokin's EGFR×HER3 Bispecific Antibody ADC Successfully Completes Phase III Trial for Advanced Esophageal Cancer
On November 17, Biokin announced that the EGFR×HER3 bispecific antibody-drug conjugate (ADC) reached both primary endpoints of progression-free survival (PFS) and overall survival (OS) in the pre-specified interim analysis of a Phase III clinical trial for advanced esophageal squamous cell carcinoma, as determined by the Independent Data Monitoring Committee (iDMC).
5) BeOne Medicines' HER2 Bispecific Antibody + PD-1 Phase III Trial Succeeds
On November 17, BeOne Medicines announced positive results from the Phase III HERIZON-GEA-01 study. The study aimed to evaluate the efficacy and safety of the HER2-targeted bispecific antibody zenidatamab alone or in combination with the PD-1 inhibitor tislelizumab, in addition to combined chemotherapy, as a first-line treatment for HER2-positive locally advanced or metastatic gastric or gastroesophageal adenocarcinoma (GEA, including gastric cancer, gastroesophageal junction adenocarcinoma, and esophageal cancer).
/ 02 /
Overseas Pharmaceutical News
1) Roche's New Generation Oral SERD Drug Phase III Study Successful
On November 18, Roche announced positive results from the Phase III lidERA study in breast cancer. The study evaluated the efficacy and safety of the investigational drug giredestrant compared to standard endocrine monotherapy as adjuvant treatment for patients with intermediate- to high-risk Stage I-III ER-positive, HER2-negative breast cancer. The study met its primary endpoint in a pre-planned interim analysis, with giredestrant demonstrating superiority over standard endocrine therapy in improving invasive disease-free survival (iDFS). The lidERA study is the first Phase III clinical trial of a selective estrogen receptor degrader (SERD) to show significant benefit in the adjuvant setting.
2) $3.05 Billion, Johnson & Johnson Acquires Halda
On November 17, Johnson & Johnson announced a full-cash acquisition of Halda Therapeutics, a pioneer in RIPTAC technology, for $3.05 billion. The latter's lead pipeline, HH-0915, intended for the treatment of prostate cancer, has demonstrated excellent efficacy potential in preliminary clinical trials.
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.
